Table 1 Main characteristics of the studies included
Study | Study design | Study period | Study region | Cancer type | ICI treatment | Sample size | Age (years) | Gender (male/female) | TNM stage (I/II/III/IV) | Outcomes | NOS Score |
|---|---|---|---|---|---|---|---|---|---|---|---|
Li. Q et al. 2023 (D) | R | 02/2018-02/2019 | China | HCC | Anti-PD-1 inhibitors | 98 | 52d | 66/32 | - | ALI (OS, PFS) | 7 |
Li. Q et al. 2023 (V) | R | 04/2019-04/2020 | China | HCC | Anti-PD-1 inhibitors | 52 | - | 44/8 | - | ALI (OS) | 6 |
Yamaguchi et al. 2023 | R | 12/2020-03/2022 | Japan | NSCLC | Nivolumab plus ipilimumab | 101 | 31/70f | 83/18 | - | ALI (OS, PFS) | 7 |
Liu et al. 2023 | R | 01/2019-12/2021 | China | HCC | ICIs | 151 | 57 ± 9.1 | 124/27 | 4/55/70/22 | ALI (OS, PFS) | 7 |
Hatanaka et al. 2023 | R | 09/2020-01/2022 | Japan | HCC | Atezolizumab and bevacizumab | 405 | 74 (68–79)b | 328/77 | - | HCC-GRIm-Score (OS) | 8 |
Nakazawa et al. 2023 | R | 10/2017-12/2018 | Japan | GC | Nivolumab | 58 | 66d | 45/13 | - | GRIm (OS, PFS) | 6 |
Minichsdorfer et al. 2023 | R | 01/2015-11/2016 | Austria | Cancer | Pembrolizumab, Nivolumab | 114 | 60 (22–88)a | 74/40 | - | GRIm (OS, PFS) | 7 |
Holtzman et al. 2022 (A) | R | 06/2016-12/2020 | Israeli | NSCLC | Pembrolizumab | 302 | 70 (36–97)a | 200/102 | - | ALI (OS) | 7 |
Holtzman et al. 2022 (B) | R | 06/2016-12/2020 | Israeli | NSCLC | Pembrolizumab | 121 | 66 (35–87)a | 74/47 | - | ALI (OS) | 7 |
Qi et al. 2021 | R | - | China | SCLC | Atezolizumab | 53 | 26/27e | 34/19 | - | ALI (OS) | 6 |
Mountzios et al. 2021 (A) | R | - | Greece, Germany | NSCLC | Anti-PD-L1 inhibitors | 460 | 67 ± 10 | 324/136 | - | ALI (OS, PFS) | 8 |
Mountzios et al. 2021 (B) | R | - | Greece, Germany | NSCLC | Anti-PD-L1 inhibitors | 212 | 67 ± 10 | 137/75 | - | ALI (OS, PFS) | 7 |
Li, Y et al. 2021 (T) | R | 01/2018-12/2019 | China | HCC | Pembrolizumab, Nivolumab, Toripalimab, Sintilimab, Tislelizumab, Camrelizumab | 181 | 32/129c | 157/24 | - | GRIm (OS), HCC-GRIm score (OS) | 6 |
Li, Y et al. 2021 (V) | R | 01/2020-09/2020 | China | HCC | Pembrolizumab, Nivolumab, Toripalimab, Sintilimab, Tislelizumab, Camrelizumab | 80 | 25/55c | 45/35 | - | GRIm (OS), HCC-GRIm score (OS) | 7 |
Lenci et al. 2021 | R | 07/2017-07/2020 | Italy | NSCLC | Pembrolizumab | 135 | 71 (44–91)a | 84/51 | - | GRIm (OS, PFS) | 7 |
Al Darazi et al. 2020 | R | 02/2015-12/2018 | French | Cancer | ICIs | 259 | 63 (18–83)a | 169/90 | - | GRIm (OS) | 7 |
Adachi et al. 2020 | R | 12/2015-12/2018 | Japan | NSCLC | Nivolumab | 296 | 70 (64-76)b | 206/90 | - | ALI (OS, PFS) | 8 |
Minami et al. 2019 | R | 12/2015-10/2018 | Japan | NSCLC | Nivolumab, Pembrolizumab, Atezolizumab | 76 | - | 49/27 | - | GRIm (OS, PFS) | 7 |
Shiroyama et al. 2018 | R | 12/2015-05/2016 | Japan | NSCLC | Nivolumab | 201 | 68 (27–87)a | 135/66 | - | ALI (PFS) | 7 |